Copyright
©The Author(s) 2024.
World J Nephrol. Dec 25, 2024; 13(4): 98709
Published online Dec 25, 2024. doi: 10.5527/wjn.v13.i4.98709
Published online Dec 25, 2024. doi: 10.5527/wjn.v13.i4.98709
Ref. | Medication | Initial dose | Taper | Total exposure |
Lv et al[63] | Methylprednisolone | 0.4 mg/kg orally once daily | Reduce daily dose by 4 mg every month | 6 months |
Lv et al[64] | Methylprednisolone | 0.6 to 0.8 mg/kg orally once daily | Reduce daily dose by 8 mg every month | 6 months |
Manno et al[65] | Prednisone | 1 mg/kg orally per day | Reduce daily dose by 0.2 mg/kg every month | 6 months |
Lv et al[66] | Prednisone | 0.8 to 1 mg/kg orally per day | Reduce daily dose by 5 to 10 mg every 2 weeks | 6 months |
Pozzi et al[67] | Methylprednisolone | Methylprednisolone 1 g IV for 3 days, followed by prednisolone | None | 6 months |
Rauen et al[68] | Prednisolone/prednisone | Prednisolone or prednisone 05 mg/kg orally ever other day | None | 6 months |
Fellström et al[59] | TRF- budesonide | 16 mg orally daily | Reduce dose to 8 mg once daily for 2 weeks | 9 months |
- Citation: Salvadori M, Rosso G. What is new in the pathogenesis and treatment of IgA glomerulonephritis. World J Nephrol 2024; 13(4): 98709
- URL: https://www.wjgnet.com/2220-6124/full/v13/i4/98709.htm
- DOI: https://dx.doi.org/10.5527/wjn.v13.i4.98709